GLI1 and colorectal carcinoma: Indeed, we described that in KRASG13D-driven CRC, chemotherapy resistance is directed by the concurrent activation of the HH-GLI and NOTCH pathways and the inhibition of both is crucial to revert the resistant phenotype.